ABBV vs EDIT · P/E 81, rev $61.16B vs rev $32.3M
AbbVie Inc (ABBV) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. EDIT currently screens at market cap $375.2M.
Not investment advice. Open the ABBV and EDIT stock pages for the full models.
Not investment advice.